Mobile

Phase II, open, single group,multicentre study to evaluate the efficacy and safety of Somatuline Autogel® (120 mg) administered every 4 weeks by deep subcutaneous injection in the tumour´s growth stab...

Update Il y a 4 ans
Reference: EUCTR2004-002871-18

Phase II, open, single group,multicentre study to evaluate the efficacy and safety of Somatuline Autogel® (120 mg) administered every 4 weeks by deep subcutaneous injection in the tumour´s growth stabilization of patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate, in patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy at the moment of study´s inclusion, the efficacy of Somatuline Autogel in tumour´s growth stabilization.

Inclusion criteria

  • Patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy

Links